TABLE 20Measures of functional ability in included studies: rivastigmine vs placebo

StudySubgroupOutcomeTypeArmRivastigminePlacebop-value
nMean (SD)nMean (SD)
Feldman and Lane (2007)138ITT populationPDS – 26 weeksMCb.i.d.227−2.6 (11.1)221−4.9 (11.2)≤ 0.001a
t.i.d.225−1.5 (11.2)221−4.9 (11.2)< 0.05a
LOCF analysisPDS – 26 weeksMCb.i.d.207−1 (11.4)209−4.7 (11.3)≤ 0.001a
t.i.d.195−2.3 (11.5)209−4.7 (11.3)< 0.05a
Mowla et al. (2007)139OC populationADL – 12 weeksA3425.3 (6.6)3227.1 (6.9)0.283b
MC341.2 (2.6)32−0.68 (1.3)0.58c
Winblad et al. (2007)140LOCF analysisADCS-ADL – 16 weeksMC10d247−0.6 (9.43)e281−1.6 (7.96)fNSg
20g2630.4 (9.73)e281−1.6 (7.96)d< 0.05e
Oral254−0.4 (7.97)e281−1.6 (7.96)eNSf
ADCS-ADL – 24 weeksMC10e247−0.1 (9.1)281−2.3 (9.4)0.01g
20h2630 (11.6)281−2.3 (9.4)0.02g
Oral254−0.5 (9.5)281−2.3 (9.4)0.04g

A, absolute value; b.i.d., twice a day; MC, mean change; NS, not statistically significant; t.i.d, three times a day.

a

Mantel–Haenszel test blocking for centre.

b

Student's t-test (two-tailed) (calculated by reviewer).

c

Post hoc Tukey test (note: t-test p < 0.001).

d

A 10-cm2 rivastigmine patch – equivalent to 9.5 mg/day.

e

Data extracted from figure.

f

Two-way analysis of covariance (ANCOVA) (explanatory variables: treatment, country and baseline scores).

g

A 20-cm2 rivastigmine patch – equivalent to 17.4 mg/day.

From: 3, Assessment of clinical effectiveness

Cover of The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model
The Effectiveness and Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer's Disease (Review of Technology Appraisal No. 111): A Systematic Review and Economic Model.
Health Technology Assessment, No. 16.21.
Bond M, Rogers G, Peters J, et al.
Southampton (UK): NIHR Journals Library; 2012 Apr.
© 2012, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.